Related Experiment Video

Updated: Jun 18, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

Chromogranin A: a novel susceptibility gene for essential hypertension

Bhavani S Sahu1, Parshuram J Sonawane, Nitish R Mahapatra

  • 1Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India.

Cellular and Molecular Life Sciences : CMLS
|November 28, 2009
PubMed

Insights

Chromogranin A (CHGA) is crucial in cardiovascular health. Genetic variations and altered levels of CHGA and its peptide catestatin are linked to essential hypertension, identifying CHGA as a novel susceptibility gene.

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Genetics

Background:

  • Chromogranin A (CHGA) is a protein found in endocrine, neuroendocrine, and neuronal cells.
  • While known as a neuroendocrine tumor marker, CHGA's role in cardiovascular diseases like essential hypertension (EH) is emerging.
  • CHGA functions as a prohormone for bioactive peptides, including vasostatin-I and catestatin, which regulate cardiovascular functions.

Purpose of the Study:

  • To investigate the role of Chromogranin A (CHGA) and its derived peptides in essential hypertension (EH).
  • To explore the impact of genetic variations in the CHGA gene on autonomic activity and blood pressure.

Main Methods:

  • Analysis of CHGA and catestatin expression levels in EH.
  • Examination of genetic variants in human CHGA gene regions (promoter, catestatin, 3'-untranslated).
  • Gene ablation and transgenic expression studies in mice to assess cardiovascular effects.

Main Results:

  • CHGA is over-expressed, while catestatin is diminished in essential hypertension.
  • Genetic variants in the CHGA gene influence autonomic activity and blood pressure.
  • CHGA gene ablation in mice leads to severe hypertension and ventricular hypertrophy.
  • CHGA gene or catestatin administration normalizes blood pressure in knockout mice.

Conclusions:

  • Chromogranin A (CHGA) plays a significant role in cardiovascular regulation.
  • Altered CHGA and catestatin levels and genetic variations are associated with essential hypertension.
  • CHGA is identified as a novel susceptibility gene for essential hypertension.

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

Related Concept Videos

Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...